Figure 1. Micrographs of spinal cord motoneurons showing SOD1-immunoreactive inclusions.
Image credit: Forsberg, et. al. 2010 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! TREAT ALS Research Grants
Sponsor: ALS Association
Description: The program is designed to support preclinical testing and development of therapeutics for ALS. This call supports the preclinical assessment of therapeutics for ALS pre-IND with a likely chance of reaching the clinic within 3 years. The proposed studies are expected to be product-driven and focused on therapeutics. The maximum award is $500,000 USD for 2 years. Projects supported include: (1) Testing of compounds of lead molecules in mouse models of ALS; (2) Development of pharmacologic agents through ADMET phase; (3) Design and implementation of full-scale, pilot current Good Manufacturing Practice (cGMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials. It is anticipated that the agents and/or data generated from these awards will lead to the advancement of new therapies for ALS. Industry partners and collaborative teams with appropriate expertise are strongly encouraged.
Deadline: Preliminary proposals due by July 6, 2018.



NEW! Accelerating Drug Discovery for FTD
Sponsor: ADDF and AFTD
Description: Through this program, the Association for FTD, in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF), seeks to advance and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs. Current funding priorities for this program include: (1) Lead optimization of novel disease-modifying compounds (e.g., medicinal chemistry refinement, in vitro ADME) and (2) Testing of novel compounds, biologics, or repurposed drugs in relevant animal models (e.g., in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, preliminary rodent tolerability studies). The award is $100,000 – $150,000 USD for 1 year with the possibility of renewal.
Deadline: Application due by July 13, 2018.



NEW! Beckman Young Investigator Awards
Sponsor: Arnold and Mabel Beckman Foundation
Description: The Beckman Young Investigator (BYI) Program provides research support to the most promising young faculty members in the early stages of their academic careers in the chemical and life sciences, particularly to foster the invention of methods, instruments and materials that will open up new avenues of research in science. Grants of up to $600,000 over four years will be awarded. The BYI program is open to those within the first three years of a tenure-track position, or an equivalent independent research appointment, at a United States academic or non-profit institution.
Deadline: Letter of Intent due by August 6, 2018.



NEW! Beryl Bayley MND Postdoctoral Fellowship
Sponsor: MND Australia
Description: MND Australia’s Postdoctoral Fellowships aim to encourage young researchers to focus their interest on classical forms of MND. Postdoctoral scientists with a track record in areas of neuroscience related to MND and no more than three years postdoctoral research experience. Applicants must be Australian citizens or have permanent resident status. Salary for a full-time research fellow will be funded at $100,000/yr for a period of up to three years. Applications will begin to be accepted in June.
Deadline: Application due by August 31, 2018.



NEW! Betty Laidlaw Prize for MND Research
Sponsor: MND Australia
Description: The Betty Laidlaw MND Research Prize aims to reward an outstanding mid-career researcher with a demonstrated background of excellence in neuroscience research. The Prize is for an innovative 12-month project to advance the understanding of classical MND with a clear potential for effective treatments. It aims to support research commencing in the calendar year 2017. The award is a maximum of $250,000 AUS for one year. Applications will begin to be accepted in June 2018.
Deadline: Application due by August 31, 2018.



NEW! Bill Gole MND Postdoctoral Fellowship
Sponsor: MND Australia
Description: MND Australia’s Postdoctoral Fellowships aim to encourage young researchers to focus their interest on classical forms of MND. Postdoctoral scientists with a track record in areas of neuroscience related to MND and no more than three years postdoctoral research experience. Applicants must be Australian citizens or have permanent resident status. Salary for a full-time research fellow will be funded at $100,000/yr for a period of up to three years. Applications will begin to be accepted in June.
Deadline: Application due by August 31, 2018.



Roger de Spoelberch Prize
Sponsor: Roger de Spoelberch Foundation
Description: Each year, the Foundation awards the Roger de Spoelberch Prize to a winner for a clinical and basic scientific research project in the area of neurodegenerative diseases and psychiatric disorders. The value of the prize currently amounts to 750,000 euros.
Deadline: Application due by June 29, 2018.



Clinical Research Fellowships
Sponsor: AFM Telethon
Description: These grants fund projects which aim to improve the management of patients, the knowledge of neuromuscular diseases and their progression, as well as the quality of life of patients affected by neuromuscular disorders, including in the following domains: (1) organization of care, (2) evaluation criteria, and (3) telemedicine. Researchers across the globe are invited to apply. The award is one year with the possibility of renewal for a second year.
Deadline: Application due by July 3, 2018.



Postdoctoral Fellowships (Scientific Research)
Sponsor: AFM Telethon
Description: This international call for proposals, open to both French and foreign groups, aims to support research which will: (A) increase our understanding of the neuromuscular system or (B) encourage the development of therapies for neuromuscular diseases and rare genetic disease. Concerning projects on ALS, priority will be given to therapeutic innovation. The award is for one year, with the possibility of a one year renewal.
Deadline: Application due by July 3, 2018.



Research Grants
Sponsor: AFM Telethon
Description: This international call for proposals, open to both French and foreign groups, aims to support research which will: (A) increase our understanding of the neuromuscular system or (B) encourage the development of therapies for neuromuscular diseases and rare genetic disease. Concerning projects on ALS, priority will be given to therapeutic innovation.
Deadline: Application due by July 3, 2018.



Research Grants (Clinical Care and Management)
Sponsor: AFM Telethon
Description: These grants fund projects which aim to improve the management of patients, the knowledge of neuromuscular diseases and their progression, as well as the quality of life of patients affected by neuromuscular disorders, including in the following domains: (1) organization of care, (2) evaluation criteria, and (3) telemedicine. Researchers across the globe are invited to apply.
Deadline: Application due by July 3, 2018.



AHA and Allen Initiative in Brain Health and Cognitive Impairment
Sponsor: American Heart Association and the Paul G. Allen Frontiers Group
Description: The AHA and Paul G. Allen Frontiers Group, with additional funding contributors including the Oskar Fischer Project, will grant a competitive basic science research award(s) of up to $43 million over eight years to one or more highly inspiring and innovative integrated team(s). New frontiers of discovery in brain health, and more specifically in cognitive impairment, will be opened when expertise and novel advances are shared and leveraged among basic and clinical cerebrovascular scientists and neuroscientists. Such integrative studies have the potential to bring truly novel directions of inquiry to the current incremental progress in the field of neurodegeneration.
Deadline: Application due by July 6, 2018.



Nonclinical and Early-Phase Clinical Development for Biologics
Sponsor: NINDS, CREATE Bio Development Track
Description: This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial will be funded. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).
Deadline: Application due by July 18, 2018.



Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases
Sponsor: NINDS
Description: The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients. Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials. The studies supported through this FOA should be clinical observational studies. No interventional studies will be supported via this funding mechanism.
Deadline: Application due by August 17, 2018.



Research Grants
Sponsor: John Templeton Foundation
Description: The Genetics Funding Area seeks to advance genetics research by supporting novel approaches and contrarian projects, especially research that is undervalued by traditional funding sources. In addition to basic and translational research, this Funding Area supports educational programs that increase public awareness concerning the ways in which genetics-related research and its applications advance human well-being at the individual, familial, and societal levels. Awards are given for no more than 3 years. Both grants of at least or at most $234,800 USD are offered depending on the project.
Deadline: Online funding inquiry (OFI) due by August 31, 2018.



Research Grants
Sponsor: MND Australia
Description: These grants provide seed-funding for research that is innovative and has a clear relationship to the causes, treatments or cures of MND or the support of people living with MND. Grants-in-aid support research for one year commencing in the calendar year 2018. The maximum award is up to $100,000 AUS. Applications will begin to be accepted in June.
Deadline: Application due by August 31, 2018.



Tools to target, identify and characterize non-neuronal cells in the brain.
Sponsor: NIH BRAIN Initiative
Description: The purpose of this Funding Opportunity Announcement [FOA] submitted through the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to stimulate the development and validation of novel tools and analytical methods to target, identify and characterize non-neuronal cells in the brain.
Deadline: Letter of Intent due by September 4, 2018.



Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by October 8, 2018.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Clinical Neuroscience Research Grants
Sponsor: Dana Foundation
Description: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.
Deadline: Applications are accepted on a rolling basis.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications will be accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Transformational Research: Canada 2018
Sponsor: Weston Brain Institute
Description: This program funds transformative, novel, high-risk, high-reward translational research projects with excellent preliminary data aimed at accelerating the development of therapies for neurodegenerative diseases of aging including FTD. A maximum of $1,500,000 over up to 3 years per project. PIs must be at or above the level of Assistant Professor or equivalent, work in Canada at least 30% of the time, and be affiliated with a CRA-qualified institution.
Deadline: February 15, 2018 (extended).



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail